Tirzepatide

Details of the Concept

Tirzepatide is a long-acting dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, administered subcutaneously once weekly. It is approved for type 2 diabetes management (Mounjaro) and chronic weight management in adults with overweight or obesity (Zepbound). Compared with GLP-1 receptor agonists alone (e.g. semaglutide), the addition of GIP receptor agonism produces greater and more sustained weight loss (12–21% in obesity trials). In the cardiovascular space, the SUMMIT trial (NEJM 2025) established tirzepatide as the first pharmacotherapy to demonstrate a significant reduction in a hard cardiovascular composite outcome (CV death or worsening HF) in patients with obesity-phenotype HFpEF.

Key Facts

Pharmacology

• Dual GIP and GLP-1 receptor agonist; "imbalanced and biased" — differential receptor engagement compared with native GIP and GLP-1 (Willard et al., 2020)
• Once-weekly SC injection; dose escalation: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg (2.5 mg increase every 4 weeks)
• Weight loss: 12–21% in obesity trials (SURMOUNT series) — exceeds GLP-1 RA monotherapy (semaglutide ~14–17%)
• GIP receptor agonism: in addition to GLP-1 effects (appetite suppression, delayed gastric emptying), GIP agonism may independently reduce adipose tissue inflammation; GIP receptors are abundant in epicardial adipocytes
• Systolic blood pressure lowering and modest heart rate increase also observed

SUMMIT Trial — Obesity-HFpEF (NEJM 2025)

• Population: 731 patients; HFpEF (LVEF ≥50%) + obesity (BMI ≥30); NYHA II–IV; mean age 65.2y; 53.8% women; mean BMI 38.3; 129 centres; 9 countries; median follow-up 104 weeks
• Eligibility note: NT-proBNP elevation NOT mandatory — recognising adiposity-mediated suppression of natriuretic peptides in obese HFpEF patients
• Dose: Tirzepatide up to 15 mg SC weekly vs placebo; on background usual therapy

Primary endpoint 1 — CV death or worsening HF event (time-to-first event):

• 36 (9.9%) tirzepatide vs 56 (15.3%) placebo
• HR 0.62 (95% CI 0.41–0.95; P=0.026)
• Worsening HF events: HR 0.54 (95% CI 0.34–0.85)
• Worsening HF requiring hospitalisation: HR 0.44 (95% CI 0.22–0.87)
• CV death: HR 1.58 (NS) — numerically higher; underpowered

Primary endpoint 2 — KCCQ-CSS at 52 weeks:

• +19.5 pts tirzepatide vs +12.7 pts placebo
• Between-group difference 6.9 pts (95% CI 3.3–10.6; P<0.001)

Key secondary endpoints (all P<0.001):

• Body weight: −13.9% vs −2.2% (between-group difference −11.6 pp)
• 6-minute walk distance: +26.0m vs +10.1m (median difference +18.3m)
• High-sensitivity CRP: −38.8% vs −5.9% (difference −34.9 pp)

All-cause death: 19 vs 15; HR 1.25 (95% CI 0.63–2.45) — NS; numerically higher with tirzepatide; trial underpowered for mortality

(sources/tirzepatide-hfpef-summit-nejm-2025, rating: very high)

Mechanism of Benefit in HFpEF

• Weight loss reduces visceral and epicardial fat → lowers plasma volume expansion, pericardial restraint, and ventricular interdependence
• CRP reduction (−38.8%) indicates systemic anti-inflammatory effect — targeting the inflammatory-metabolic HFpEF substrate
• GIP receptor agonism in epicardial adipocytes may suppress local inflammation and adjacent myocardial fibrosis beyond GLP-1 alone (distinct mechanistic advantage over semaglutide)
• Systolic BP lowering may provide additional hemodynamic benefit in the load-sensitive HFpEF ventricle
• Benefits consistent across prespecified subgroups including those with NT-proBNP <200 pg/mL — suggesting benefit even in low-NP obesity-HFpEF

SYNERGY-NASH Phase 2b — MASH

• Population: 190 patients with MASH and moderate or severe fibrosis (F2–F3); tirzepatide 5 mg, 10 mg, or 15 mg vs placebo SC weekly for 52 weeks
• MASH resolution without worsening fibrosis: 56% (5 mg), 62% (10 mg), 62% (15 mg) vs 44% (placebo) — all arms superior; dose-response curve P<0.001
• ≥1 stage fibrosis reduction without worsening MASH: 55% (5 mg), 51% (10 mg), 51% (15 mg) vs 30% (placebo)
• Body weight: mean reduction up to ~15% at 15 mg; improved lipids, insulin resistance, and HbA1c vs placebo
• Adverse events: mild-to-moderate gastrointestinal events most common, consistent with GLP-1 RA class
  (sources/masld-nejm-2025, rating: high)

Comparison with Semaglutide (STEP-HFpEF, NEJM 2023)

Contradictions / Open Questions

• Numerically higher all-cause and CV deaths: All-cause deaths 19 tirzepatide vs 15 placebo (HR 1.25, NS) and CV/undetermined deaths 10 vs 5 (HR 1.58, NS) are concerning, though underpowered. Authors argue HFpEF CV deaths frequently do not reflect HF progression (most not preceded by worsening HF). Long-term outcome trials (e.g. SELECT-equivalent in HFpEF) are needed. (sources/tirzepatide-hfpef-summit-nejm-2025, rating: very high)
• Primary endpoint revision concern: Endpoints were formally amended ~1 year before trial end following FDA discussions; though prior to unblinded efficacy analysis, this creates analytical uncertainty around the alpha allocation and endpoint selection. (sources/tirzepatide-hfpef-summit-nejm-2025, rating: very high)
• Mortality benefit unestablished: Trial was powered for the composite HF endpoint and KCCQ, not mortality. In prior long-term GLP-1 RA trials (SELECT: semaglutide; SUSTAIN-6), GLP-1 RA class reduced CV and all-cause death over 2+ years. Whether tirzepatide reduces mortality in HFpEF over longer follow-up remains unproven. (sources/tirzepatide-hfpef-summit-nejm-2025, rating: very high)
• BMI threshold excludes visceral adiposity without obesity: BMI ≥30 misses patients with waist-to-height ratio >0.5 and excess visceral adiposity but BMI <30 — a group that may also have obesity-mediated HFpEF and could benefit. (sources/tirzepatide-hfpef-summit-nejm-2025, rating: very high)
• Mechanism of benefit — weight loss vs. direct drug effects: As with semaglutide, the relative contributions of weight loss, direct GLP-1 signaling, and novel GIP receptor agonism in epicardial adipose tissue cannot be cleanly disentangled from this trial design alone. (sources/tirzepatide-hfpef-summit-nejm-2025, rating: very high)
• No diabetes population: SUMMIT excluded T2DM patients. Whether benefits persist in the obesity-HFpEF + T2DM phenotype (where SGLT2i use is higher) requires separate study. (sources/tirzepatide-hfpef-summit-nejm-2025, rating: very high)
• Applicability to HFrEF: No data on tirzepatide in HFrEF + obesity. GLP-1 RA class has shown neutral or harmful signals in prior HFrEF trials (LIVE, FIGHT); this class effect warrants caution pending specific RCT data. (sources/tirzepatide-hfpef-summit-nejm-2025, rating: very high)

Connections

• Related to entities/HFpEF — primary therapeutic target; SUMMIT trial; obesity-HFpEF phenotype
• Related to entities/Obesity — approved indication; mechanistic foundation
• Related to entities/Semaglutide — GLP-1 RA comparator; STEP-HFpEF context; tirzepatide achieves greater weight loss
• Related to concepts/Visceral-Adiposity — epicardial fat reduction; GIP receptor expression in epicardial adipocytes
• Related to concepts/Obesity-Paradox — SUMMIT extends refutation to hard cardiovascular outcomes
• Related to entities/MASLD — SYNERGY-NASH phase 2b: MASH resolution 56–62%; fibrosis reduction 51–55%

Sources

• sources/tirzepatide-hfpef-summit-nejm-2025
• sources/masld-nejm-2025